Search Results - (Author, Cooperation:G. Finazzi)

2015-07-15

Nature Publishing Group (NPG)

0028-0836

1476-4687

Biology

Chemistry and Pharmacology

Medicine

Natural Sciences in General

Physics

Adenosine Triphosphate/metabolism ; Aquatic Organisms/cytology/enzymology/genetics/*metabolism ; Carbon Cycle ; Carbon Dioxide/*metabolism ; Diatoms/*cytology/enzymology/genetics/*metabolism ; Ecosystem ; Mitochondria/*metabolism ; Mitochondrial Proteins/deficiency/metabolism ; NADP/metabolism ; Oceans and Seas ; Oxidation-Reduction ; Oxidoreductases/deficiency/metabolism ; Phenotype ; *Photosynthesis ; Plant Proteins/metabolism ; Plastids/*metabolism ; *Proton-Motive Force

2013-09-07

American Association for the Advancement of Science (AAAS)

0036-8075

1095-9203

Biology

Chemistry and Pharmacology

Computer Science

Medicine

Natural Sciences in General

Physics

Arabidopsis/genetics/*metabolism ; Arabidopsis Proteins/genetics/*metabolism ; Light ; *Photosynthesis ; Potassium Channels/genetics/*metabolism ; Potassium Channels, Tandem Pore Domain/genetics/*metabolism ; Recombinant Proteins/genetics/metabolism ; Thylakoids/*metabolism/ultrastructure

1365-2133

Blackwell Publishing Journal Backfiles 1879-2005

Medicine

Electronic Resource

0005-2728

Light harvesting ; Membrane energization ; Photosystem II ; Reaction center ; [abr] 9-aa; 9-aminoacridine ; [abr] DCMU; 3-(3,4 dichlorophenyl)-1,1 dimethylurea ; [abr] PS I; Photosystems I ; [abr] PS II; Photosystems II respectively ; [abr] Q"a; the quinone primary acceptor of PS II ; [abr] Δψ; electric potential across the thylakoid membrane

Elsevier Journal Backfiles on ScienceDirect 1907 - 2002

Biology

Chemistry and Pharmacology

Medicine

Physics

Electronic Resource

0005-2728

Energy transfer ; Excitation energy ; Light harvesting complex phosphorylation ; Localized proton ; Photosystem II regulation ; Reaction center

Elsevier Journal Backfiles on ScienceDirect 1907 - 2002

Biology

Chemistry and Pharmacology

Medicine

Physics

Electronic Resource

0005-2728

Carotenoid de-epoxidation ; Fluorescence quenching ; Localized proton ; Photosystem II ; Uncoupler

Elsevier Journal Backfiles on ScienceDirect 1907 - 2002

Biology

Chemistry and Pharmacology

Medicine

Physics

Electronic Resource

0167-4838

Light harvesting ; Localized proton ; Photosystem II ; Proton effect ; Reaction center

Elsevier Journal Backfiles on ScienceDirect 1907 - 2002

Biology

Chemistry and Pharmacology

Medicine

Electronic Resource

1432-0584

Key words Treatment ; Essential thrombocythemia ; Leukemogenic risk

Springer Online Journal Archives 1860-2000

Medicine

Abstract  Acute leukemia and myelodysplastic syndromes are rare, but almost invariably fatal, evolutions of essential thrombocythemia (ET). Three major factors are associated with blastic transformation: cytogenetic abnormalities, myelofibrotic features, and the use of cytotoxic agents. Hematological malignancies have been reported in ET patients after treatment with alkylating agents, such as busulphan, as well as other cytoreductive drugs, such as hydroxyurea. Concerns about leukemogenicity have led some to suggest limiting the indications of these drugs to patients at higher risk of bleeding and thrombosis. Major risk factors for thrombosis are age above 60 years and a previous thrombotic event, whereas an increased bleeding tendency has been reported with platelet counts in excess of 1000–1500×109/l. No myelosuppressive therapy is recommended for younger patients if they are asymptomatic or their platelet counts are below 1500×109/l. The threshold of 1500×109/l is controversial, however, and cytoreduction can be considered when platelets are above 1000×109/l or in the presence of risk factors for cardiovascular disease. In the presence of thrombotic events or extreme thrombocytosis, young ET patients can be managed with cytoreductive agents theoretically devoid of leukemogenic risk, such as a-interferon or anagrelide. Nevertheless, the mutagenic risk of anagrelide has not been investigated in long-term follow-up studies, and the ultimate place of these 'new' drugs in the management of ET patients remains to be established in prospective and controlled clinical trials.

Electronic Resource

1590-3478

cerebral ischemia ; carotid stenosis ; protein S ; hypercoagulability

Springer Online Journal Archives 1860-2000

Medicine

Sommario I deficit congeniti di proteina S costituiscono un importante fattore di rischio di trombosi venosa e più raramente arteriosa. Descriviamo il caso di una paziente di 35 anni con ischemia cerebrale, deficit di proteina S e stenosi carotidea; lo studio familiare ha evidenziato altri membri con lo stesso difetto di proteina S e con storia di manifestazioni trombotiche venose.

Abstract Congenital protein S deficiency is an important risk factor for venous and, more rarely, arterial thrombosis. Here, we describe the case of a 35-year old patient with cerebral ischemia, protein S deficiency and carotid stenosis. Other members of the family were found to have the same protein S deficit and a history of venous thrombotic manifestations.

Electronic Resource

1590-3478

essential thrombocytemia ; stroke ; large artery obstruction

Springer Online Journal Archives 1860-2000

Medicine

Sommario La Trombocitemia Essenziale è una malattia mieloproliferativa a cause ignota caratterizzata da un aumentato numero di piastrine apparentemente normali. Associata a numerose e generalmente lievi complicazioni ischemiche, più raramente è stata riportata la sua associazione a stroke acuto da documentata ostruzione dei grossi vasi. Noi qui descriviamo 6 pazienti con stroke ischemico acuto associato a Trombocitemia Essenziale. Si tratta di 4 uomini e 2 donne di età media 61,7 anni (limiti 49–78). La diagnosi di Trombocitemia Essenziale fu fatta dopo l'evento ischemico. Il numero di piastrine non è mai risultato particolarmente elevato in fase ictale. In 2 pazienti non vi erano fattori maggiori di rischio cardiovascolare. In 3 vi era interessamento della circolazione posteriore, in 2 della anteriore e in uno del territorio di confine. In tutti è stata documentata ostruzione di grossi vasi arteriosi extra o intracranici. Tutti i pazienti sono stati trattati con terapia antiaggregante (aspirina o ticlopidina). L'evoluzione è stata favorevole in 3 pazienti, discreta in 1 e mediocre in 2. Si ipotizza che la Trombocitemia Essenziale possa essere considerata tra le cause associate a stroke acuto da ostruzione dei grossi vasi.

Abstract Essential thrombocytemia (ET) is a clonal myeloproliferative disorder of unknown cause, characterized by an increased number of apparently normal platelets. It has been related to a large number of mild ischemic complications, but rarely to acute stroke associated with documented large vessel thrombosis. We report the cases of 6 patients with acute ischemic stroke associated with ET (4 men and 2 women; mean age 61.7: range 49–78 years). The diagnosis of ET followed the onset of the stroke. The number of platelets was never greatly increased at the time of the stroke, and two patients presented no major risk factors for stroke. The involvement of the posterior circulation was observed in three patients, that of the anterior circulation in two patient and that of the border territory in one. The obstruction of large intracranial or extracranial vessles was detected in all of the patients, and all of them were treated with antiplatelet agents (aspirin or ticlopidine). The outcome was good in 3 patients, fair in one and bad in two. We retain that ET might be a cause of acute ischemic stroke as a result of large vessel obstruction.

Electronic Resource